Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Lupus Science & Medicine|June 6, 2018
Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLEJoan T Merrill, Michelle A Petri, Jill Buyon, et al.
Rheumatology (Oxford, England)|August 26, 2022
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trialsIan N Bruce, Ronald F van Vollenhoven, Eric F Morand, et al.
Lupus Science & Medicine|March 7, 2024
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune diseaseScott R P McDonnell, Van Anh Nguyen, Noah M Walton, et al.
Lupus Science & Medicine|November 17, 2022
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLEErik W Anderson, Ying Jin, Andrew Shih, et al.
Lupus Science & Medicine|February 16, 2022
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a studyRichard A Furie, Douglas R Hough, Allison Gaudy, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 10, 2023
Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY TrialBrad H Rovin, Richard A Furie, Jorge A Ross Terres, et al.
Arthritis and Rheumatism|February 7, 2003
LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled studyDonato Alarcón-Segovia, James A Tumlin, Richard A Furie, et al.
Annals of the Rheumatic Diseases|February 11, 2022
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritisDavid Jayne, Brad Rovin, Eduardo F Mysler, et al.
Annals of the Rheumatic Diseases|February 13, 2025
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trialsEric F Morand, Ronald van Vollenhoven, Richard A Furie, et al.
Rheumatology (Oxford, England)|May 6, 2021
Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosusRichard A Furie, Ian N Bruce, Thomas Dörner, et al.
Pageof 8